Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Chest
|
August 31, 2020
Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium
Rachel P Rosovsky, Charles Grodzin, Richard Channick, et al.
JACC. Advances
|
February 25, 2025
Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart Disease
Richard A Krasuski, Tobore Tobore, Sean Studer, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
J Gerry Coghlan, Richard Channick, Kelly Chin, et al.
Journal of the American College of Cardiology
|
April 23, 2003
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension
Nazzareno Galiè, Alan L Hinderliter, Adam Torbicki, et al.
ERJ Open Research
|
January 23, 2023
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
J Gerry Coghlan, Sean Gaine, Richard Channick, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
July 13, 2025
Management of chronic thromboembolic pulmonary hypertension
Christoph B Wiedenroth, David Jenkins, Philippe Brenot, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases
Adam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
The New England Journal of Medicine
|
December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon, Richard Channick, Kelly M Chin, et al.
American Journal of Respiratory and Critical Care Medicine
|
October 14, 2017
Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement
Arunabh Talwar, Joe G N Garcia, Halley Tsai, et al.
Chest
|
November 19, 2019
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents
Vallerie V McLaughlin, Richard Channick, Teresa De Marco, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Chest
|
August 31, 2020
Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium
Rachel P Rosovsky, Charles Grodzin, Richard Channick, et al.
JACC. Advances
|
February 25, 2025
Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart Disease
Richard A Krasuski, Tobore Tobore, Sean Studer, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
J Gerry Coghlan, Richard Channick, Kelly Chin, et al.
Journal of the American College of Cardiology
|
April 23, 2003
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension
Nazzareno Galiè, Alan L Hinderliter, Adam Torbicki, et al.
ERJ Open Research
|
January 23, 2023
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
J Gerry Coghlan, Sean Gaine, Richard Channick, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
July 13, 2025
Management of chronic thromboembolic pulmonary hypertension
Christoph B Wiedenroth, David Jenkins, Philippe Brenot, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 22, 2019
Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases
Adam Torbicki, Marisa Bacchi, Marion Delcroix, et al.
The New England Journal of Medicine
|
December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon, Richard Channick, Kelly M Chin, et al.
American Journal of Respiratory and Critical Care Medicine
|
October 14, 2017
Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement
Arunabh Talwar, Joe G N Garcia, Halley Tsai, et al.
Chest
|
November 19, 2019
Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents
Vallerie V McLaughlin, Richard Channick, Teresa De Marco, et al.
Page
of 8